Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629206 | 0.88 | HSP90AA1 (0.51) | HSP90AA1NR3C2PDE11ASLC16A3SLC16A1 | |
| SCHEMBL1629130 | 0.87 | HSP90AA1 (0.49) | HSP90AA1NR3C2PDE11AALDH1A1POLB | |
| SCHEMBL1629115 | 0.87 | HSP90AA1 (0.51) | HSP90AA1NR3C2PDE11AMAPK14 | |
| SCHEMBL1629715 | 0.86 | HSP90AA1 (0.52) | HSP90AA1NR3C2PDE11AALDH1A1POLB | |
| SCHEMBL1217338 | 0.86 | HSP90AA1 (0.51) | HSP90AA1NR3C2PDE11AALDH1A1SLC16A3 | |
| SCHEMBL1216341 | 0.86 | HSP90AA1 (0.48) | HSP90AA1NR3C2ALDH1A1POLBKMT2A | |
| SCHEMBL1628570 | 0.85 | HSP90AA1 (0.39) | HSP90AA1NR3C2ALDH1A1L3MBTL1SLC16A3 | |
| SCHEMBL1628916 | 0.85 | HSP90AA1 (0.49) | HSP90AA1NR3C2PDE11AALDH1A1TDP1 | |
| SCHEMBL1629180 | 0.84 | HSP90AA1 (0.59) | HSP90AA1NR3C2PDE11ASLC16A3SLC16A1 | |
| SCHEMBL2079472 | 0.84 | HSP90AA1 (0.47) | HSP90AA1NR3C2PDE11AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | claimed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | claimed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NR3C2 558/4885PDE11A 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.